<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJRA</journal-id><journal-title-group><journal-title>Open Journal of Rheumatology and Autoimmune Diseases</journal-title></journal-title-group><issn pub-type="epub">2163-9914</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojra.2015.52006</article-id><article-id pub-id-type="publisher-id">OJRA-55418</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Autoantibodies in Systemic Lupus Erythematosus, on Black African Subject, in Abidjan
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>ariam</surname><given-names>Gbané-Koné</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Baly</surname><given-names>Ouattara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kouassi</surname><given-names>Jean Mermoz Djaha</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Estelle</surname><given-names>Megne</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Astrid</surname><given-names>Nawé Ngandeu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abidou</surname><given-names>Kawalé Coulibaly</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Edmond</surname><given-names>Eti</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Marcel</surname><given-names>N’zué Kouakou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Rheumatology, University Hospital Center of Cocody, Abidjan, C&amp;amp;#212te d’Ivoire</addr-line></aff><pub-date pub-type="epub"><day>03</day><month>04</month><year>2015</year></pub-date><volume>05</volume><issue>02</issue><fpage>28</fpage><lpage>35</lpage><history><date date-type="received"><day>6</day>	<month>March</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>3</month>	<year>April</year>	</date><date date-type="accepted"><day>8</day>	<month>April</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Aim: To determine the clinical and immunological characteristics of patients with systemic erythematosus lupus in Abidjan. Patients and Method: We studied 117 patients’ files with systemic lupus erythematosus aged 12 to 73 years old, who fulfilled the American College of Rheumatology (ACR)’s criteria. Antinuclear autoantibodies (ANA) were searched by indirect immunofluorescence. Anti-DNA native autoantibodies, extractable nuclear anti-antigens autoantibodies (anti-Sm, anti-SSA, anti-SSB and anti-RNP) and anti-phospholipids autoantibodies have been searched by ELISA technic. Results: The most frequent clinical manifestations were: articular damages (86.32%), cutaneous and mucosal lesions (71.79%) and fever (76.67%). Kidney damages have been noticed in 40.17%. Neurologic manifestations have been observed in 36.75%. Pericarditis and pleurisies have been noticed in 22.22% and 11.97% of cases, and anaemia in 86.32% of cases. ANA have been detected in 94.12% of cases, anti-DNA native’s autoantibodies in 73.53% and anti-Sm autoantibodies in 75% of cases. Anti-SSA and anti-SSB autoantibodies were respectively in 75% and 56.25% of cases. Anti-RNP autoantibodies were in all the patients, and anti-phospholipids autoantibodies were in 37.50% of cases. Conclusion: Systemic lupus erythematosus of Ivorian black subject is characterised by high prevalence of autoantibodies, mostly Anti-RNP.
 
</p></abstract><kwd-group><kwd>Sub-Saharan Africa</kwd><kwd> Systemic Lupus Erythematosus</kwd><kwd> Extractable Nuclear Anti-Antigens</kwd><kwd> Autoantibodies</kwd><kwd> Anti-Phospholipids Autoantibodies</kwd><kwd> ELISA</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Systemic lupus erythematosus (SLE) is an autoimmune disease, non-specific to any organ, characterised by the production of a high variety of autoantibodies, some of which have a direct pathogenic role [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] . Hormonal factors, environmental and genetics factors intervened in the physiopathology [<xref ref-type="bibr" rid="scirp.55418-ref3">3</xref>] . Clinically, SLE is characterised by its polymorphism. We have more and more data on SLE in sub-Saharan Africa [<xref ref-type="bibr" rid="scirp.55418-ref4">4</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref7">7</xref>] on black subject more specifically particular [<xref ref-type="bibr" rid="scirp.55418-ref3">3</xref>] . Many workers from English or French speaking black Africa have reported the frequency of different clinical and biological manifestations of lupus [<xref ref-type="bibr" rid="scirp.55418-ref3">3</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref7">7</xref>] .</p><p>In Ivory Coast, the study realised by Daboiko [<xref ref-type="bibr" rid="scirp.55418-ref4">4</xref>] in 2004 had mostly described epidemio-clinical aspects of SLE on black subject; our work is coming in addition to complete. It aims to describe autoantibodies profile in SLE on black African subject in Abidjan.</p></sec><sec id="s2"><title>2. Patients and Method</title><p>It was a descriptive and retrospective study, carried out on a retrospective setup over 27 years from 1987 to December 2014 the rheumatology department’s record. The following criteria were considered for the patients: should have consulted or have been hospitalized in the rheumatology department during the study period; the SLE diagnostic have been retained in front of at list 4 criteria of ACR. The patient’s age at the diagnostic period matches to the age where the patient respond to ACR criteria’s. For each patient, a form was design, which included clinical manifestations of the disease, blood numeration formula, sedimentation rate, C-reactive protein, and the 24 hours proteinuria.</p><p>Immunological investigations had anti-nuclear autoantibodies factors in all the cases; anti-DNA autoantibodies research and anti ENA (anti-Sm, anti-URN-P, anti SSA, anti SSB, Anti Scl 70); and anticardiolipins, rheumatoid factors, and anti-CCP. Immunological samples (ANA, Anti ENA, Anti CCP, Antiphospholipid) were all routed in France (Cerba laboratory) for analysis.</p><p>Antinuclear autoantibodies (AAN) were researched using indirect immunofluorescence technic. Anti-DNA native autoantibodies (anti-Sm, anti-SS-A, anti-SS-B and anti-RNP); and antiphospholipids autoantibodies (anticardiolipine: acL) have been researched by ELISA technic.</p><p>This investigation was approved by the local Ethics Committee.</p></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Prevalence</title><p>On a sample of 18076 patients hospitalised during the study period, 117 SLE files have been found, thus a 0.64% prevalence in hospitalisation.</p></sec><sec id="s3_2"><title>3.2. Age</title><p>The average age during the diagnosis was 35.76 years old, with a standard deviation of 11.956 and extremes of ages of 12 and 73 years old.</p><p>The most affected age group was that of 21 - 40 years (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="s3_3"><title>3.3. Sex</title><p>There were 115 females (98.3%) and 02 males (1.7%), with a sex ratio (F/M) of 57.5.</p></sec><sec id="s3_4"><title>3.4. Clinical Manifestations</title><p>The main clinical manifestations are illustrated on <xref ref-type="table" rid="table1">Table 1</xref>.</p><p>Articular damages constituted the most frequent clinical manifestations, because observed on 86.32% of patients. Most of the time it was arthralgia most of the time (53%). Myalgia represented 14% of cases.</p><p>An articular deformation, Jacoud’s hand, was observed on 6 female patients. Fever, was the most frequent general symptom (76.07%).</p><p>Principal cutaneous manifestations were butterfly rash (43.59%) and photosensitivity (41.90%).</p></sec><sec id="s3_5"><title>3.5. Biological Characteristics</title><p><xref ref-type="table" rid="table2">Table 2</xref> outlines the principal biological and immunological anomalies research on this study.</p><p>Anaemia was the principal haematological anomaly. Inflammatory syndrome was quasi constant (96.58% of cases).</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Distribution of SLE patients by age groups</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/2-2040152x5.png"/></fig><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical manifestations of 117 SLE monitored in Abidjan</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Clinical manifestations</th><th align="center" valign="middle" >Number of cases</th><th align="center" valign="middle" >Prevalence (%)</th></tr></thead><tr><td align="center" valign="middle" >Articular signs</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" >86.32</td></tr><tr><td align="center" valign="middle" >Arthralgia</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >53</td></tr><tr><td align="center" valign="middle" >Arthritis</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >41.90</td></tr><tr><td align="center" valign="middle" >General signs</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >76.07</td></tr><tr><td align="center" valign="middle" >Long-term fever</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >76.07</td></tr><tr><td align="center" valign="middle" >Changed general body state</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >64.10</td></tr><tr><td align="center" valign="middle" >Mucocutaneous signs</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >71.79</td></tr><tr><td align="center" valign="middle" >Facial erythema</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >43.59</td></tr><tr><td align="center" valign="middle" >Alopecia</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >31.62</td></tr><tr><td align="center" valign="middle" >Oral ulcerations</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >16.23</td></tr><tr><td align="center" valign="middle" >Photosensitivity</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >41.90</td></tr><tr><td align="center" valign="middle" >Discoid lupus</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >5.13</td></tr><tr><td align="center" valign="middle" >Neuropsychiatric signs</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >36.75</td></tr><tr><td align="center" valign="middle" >CVA<sup>*</sup></td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >6.83</td></tr><tr><td align="center" valign="middle" >Convulsions</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >17.09</td></tr><tr><td align="center" valign="middle" >Confusional syndrome</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >8.55</td></tr><tr><td align="center" valign="middle" >Psychomotor agitation</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >5.13</td></tr><tr><td align="center" valign="middle" >Pulmonary signs</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >35.04</td></tr><tr><td align="center" valign="middle" >Pleurisy</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >11.97</td></tr><tr><td align="center" valign="middle" >Pneumopathy/diffuse interstitial fibrosis</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >23.07</td></tr><tr><td align="center" valign="middle" >Kidneys signs</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >40.17</td></tr><tr><td align="center" valign="middle" >Proteinuria</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >35.04</td></tr><tr><td align="center" valign="middle" >CKD<sup>*</sup></td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >9.40</td></tr><tr><td align="center" valign="middle" >Cardiac signs</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >29.91</td></tr><tr><td align="center" valign="middle" >Pericarditis</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >22.22</td></tr><tr><td align="center" valign="middle" >Myocarditis</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >7.69</td></tr><tr><td align="center" valign="middle" >Splenic and ganglionic signs</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >11.97</td></tr><tr><td align="center" valign="middle" >Superficial adenopathy</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >11.97</td></tr><tr><td align="center" valign="middle" >Splenomegaly</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >4.27</td></tr><tr><td align="center" valign="middle" >Raynaud’s syndrome</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >8.54</td></tr></tbody></table></table-wrap><p>CVA<sup>*</sup>: Cerebral Vascular Accident; CKD<sup>*</sup>: Chronic Kidney Disease.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Biological and immunological anomalies of 117 SLE monitored in Abidjan</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Biological and immunological manifestations</th><th align="center" valign="middle" >Effectives (n)</th><th align="center" valign="middle" >Total patients (N)</th><th align="center" valign="middle" >Prevalence (%)</th></tr></thead><tr><td align="center" valign="middle" >Haematological manifestations</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" >117</td><td align="center" valign="middle" >86.32</td></tr><tr><td align="center" valign="middle" >Anaemia</td><td align="center" valign="middle" >101</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >86.32</td></tr><tr><td align="center" valign="middle" >Leukopenia</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >15.38</td></tr><tr><td align="center" valign="middle" >Thrombocytopenia</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >13.67</td></tr><tr><td align="center" valign="middle" >Inflammatory syndrome</td><td align="center" valign="middle" >113</td><td align="center" valign="middle" >117</td><td align="center" valign="middle" >96.58</td></tr><tr><td align="center" valign="middle" >Sedimentary rate</td><td align="center" valign="middle" >113</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >96.58</td></tr><tr><td align="center" valign="middle" >C reactive protein</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >39.31</td></tr><tr><td align="center" valign="middle" >ANA</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >94.12</td></tr><tr><td align="center" valign="middle" >Anti DNA native</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >73.53</td></tr><tr><td align="center" valign="middle" >Anti-ENA</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >76.20</td></tr><tr><td align="center" valign="middle" >Anti-Sm</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >75</td></tr><tr><td align="center" valign="middle" >U<sub>1</sub>RNP</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle" >Anti SSA/Ro</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >75</td></tr><tr><td align="center" valign="middle" >Anti SSB/La</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >56.25</td></tr><tr><td align="center" valign="middle" >Anti-Jo<sub>1</sub></td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >12.50</td></tr><tr><td align="center" valign="middle" >Anti-Scl70</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >12.50</td></tr><tr><td align="center" valign="middle" >Ac antiphospholipids</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >37.50</td></tr></tbody></table></table-wrap><p>ANA were positive in 94.12% of cases with a speckled most frequently aspect (58.8%) or homogenous (26.5%). Anti-DNA native were tested positive on 73.53% of cases and anti ENA on 76.20%.</p><p>Anti-Sm was positive on 75% of cases. Antiphospholipids research was positive on 37.50% of cases.</p><p>On the 26 patients who have been realised the rheumatoid factors, 14 were ended up being positives.</p><p>Eight patients have realised the anti-CCP dosage, and all of them where negatives.</p></sec></sec><sec id="s4"><title>4. Discussion</title>Limitations of the Study<p>The review of literature series only acted as a reference. Clinical signs have not been reported in the same conditions in all the series, the prevalence of a clinical manifestation changes according to whether it was considered at the moment of the diagnosis only; or during the patients monitoring, and the immunological tests have not been realised in the same conditions and with the same technics. In our case, the cost and accessibility of immunological tests (ANA, Anti ENA, Anti CCP, Antiphospholipid) constituted a barrier to diagnosis, immunological samples were all routed in France (Cerba laboratory) for analysis. All these factors may influence the prevalence of various signs and their variability from one series to another.</p><p>As Daboiko reported [<xref ref-type="bibr" rid="scirp.55418-ref4">4</xref>] in his sample of 49 lupic in Abidjan, the average age and the population reported in our study, did not have particularities. The clinical predominance is classic [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref3">3</xref>] , in fact the SLE is a young woman pathology [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref4">4</xref>] . The average age of onset was 35.76 years old. This predominance is less pronounced at the bounding ages, this confirms the hypothesis of endocrine factors implication in the disease ethiopathogeny [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] .</p><p>Our study confirms the clinical polymorphism of SLE in Abidjan and its high similitude with other regions of Africa (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>Clinical manifestations generally associated cutaneo-articular damages, kidneys, cardiovascular, pleuropulmonary and neurologic damages, with some differences according to the country studied (<xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Compared frequency of SLE ACR criteria many series of literature</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Tunisia (n = 295)</th><th align="center" valign="middle" >Morocco (n = 440)</th><th align="center" valign="middle" >Gabon (n = 37)</th><th align="center" valign="middle" >Senegal (n = 142)</th><th align="center" valign="middle" >Ivory-coast (n = 117)</th><th align="center" valign="middle" >Cameroon (n = 39)</th></tr></thead><tr><td align="center" valign="middle" >Cutaneous damages</td><td align="center" valign="middle" >82</td><td align="center" valign="middle" >85.2</td><td align="center" valign="middle" >62.1</td><td align="center" valign="middle" >90.8</td><td align="center" valign="middle" >71.79</td><td align="center" valign="middle" >_</td></tr><tr><td align="center" valign="middle" >Butterfly rash</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >43.59</td><td align="center" valign="middle" >15.4</td></tr><tr><td align="center" valign="middle" >Discoid lupus</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >27.5</td><td align="center" valign="middle" >14.53</td><td align="center" valign="middle" >5.1</td></tr><tr><td align="center" valign="middle" >Photosensitivity</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >57.7</td><td align="center" valign="middle" >41.9</td><td align="center" valign="middle" >7.7</td></tr><tr><td align="center" valign="middle" >Oral ulcerations</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >4.2</td><td align="center" valign="middle" >16.23</td><td align="center" valign="middle" >10.3</td></tr><tr><td align="center" valign="middle" >Articular damages</td><td align="center" valign="middle" >90</td><td align="center" valign="middle" >95</td><td align="center" valign="middle" >59.4</td><td align="center" valign="middle" >68.3</td><td align="center" valign="middle" >86.32</td><td align="center" valign="middle" >58.9</td></tr><tr><td align="center" valign="middle" >Seritis</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >24.1</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >9.9</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >10.3</td></tr><tr><td align="center" valign="middle" >Kidney damages</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >45.9</td><td align="center" valign="middle" >16.2</td><td align="center" valign="middle" >49.3</td><td align="center" valign="middle" >40.17</td><td align="center" valign="middle" >17.9</td></tr><tr><td align="center" valign="middle" >Neurologic damages</td><td align="center" valign="middle" >14.5</td><td align="center" valign="middle" >25.3</td><td align="center" valign="middle" >24.3</td><td align="center" valign="middle" >17.6</td><td align="center" valign="middle" >36.75</td><td align="center" valign="middle" >10.3</td></tr><tr><td align="center" valign="middle" >Anaemia</td><td align="center" valign="middle" >6.7</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >49.2</td><td align="center" valign="middle" >86.32</td><td align="center" valign="middle" >72</td></tr><tr><td align="center" valign="middle" >Leukopenia</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >19.7</td><td align="center" valign="middle" >15.38</td><td align="center" valign="middle" >56</td></tr><tr><td align="center" valign="middle" >Lymphocytopenia</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >14.8</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >44</td></tr><tr><td align="center" valign="middle" >Thrombocytopenia</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >13.4</td><td align="center" valign="middle" >13.67</td><td align="center" valign="middle" >16</td></tr><tr><td align="center" valign="middle" >AC Anti-DNA</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >73.4</td><td align="center" valign="middle" >63.8</td><td align="center" valign="middle" >45.7</td><td align="center" valign="middle" >73.53</td><td align="center" valign="middle" >73.5</td></tr><tr><td align="center" valign="middle" >Anti Sm</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >16.6</td><td align="center" valign="middle" >33.33</td><td align="center" valign="middle" >65.2</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >_</td></tr><tr><td align="center" valign="middle" >Ig aCL<sup>*</sup></td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >27.1</td><td align="center" valign="middle" >_</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >37.5</td><td align="center" valign="middle" >50</td></tr><tr><td align="center" valign="middle" >Anti-nuclear</td><td align="center" valign="middle" >92</td><td align="center" valign="middle" >95</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >97.8</td><td align="center" valign="middle" >94.12</td><td align="center" valign="middle" >86.1</td></tr></tbody></table></table-wrap><p>Ig aCL<sup>*</sup>: Ig anticardiolipin.</p><p>In our study, articular manifestations were at the first considered, followed by general manifestations and cutaneous damages common for Cameroonian series [<xref ref-type="bibr" rid="scirp.55418-ref7">7</xref>] , Moroccan [<xref ref-type="bibr" rid="scirp.55418-ref8">8</xref>] and Tunisian [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] , however for Senegalese series [<xref ref-type="bibr" rid="scirp.55418-ref6">6</xref>] and Gabonese [<xref ref-type="bibr" rid="scirp.55418-ref5">5</xref>] , cutaneous damages were most frequently followed by articular damages.</p><p>Articular damages inaugurate the disease in 50% of cases [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] . Arthralgia are frequent (53% in our series), they are often coming with myalgia. Arthritis realise habitually a bilateral and symmetric polyarthritis.</p><p>Cutaneous damage’s prevalence varies between 32% and 72% [<xref ref-type="bibr" rid="scirp.55418-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref11">11</xref>] . Butterfly rash, SLE characteristic has been noticed on 43.59% of cases in our series.</p><p>Kidney damages are the second causes mortality of SLE. Its frequency varies depending on the series between 13% and 73% [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref13">13</xref>] . In our study it was 40.17%. It was consistenly less elevated in Gabonese series (16.2%) and Cameroonian (17.9%). Glomerular damage is the characteristic lesion, it manifest by a frank proteinuria [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] .</p><p>Neurological damages constitute the third cause of SLE mortality after infectious complications and kidney damage [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] .</p><p>Neuropsychiatric manifestations have a variable frequency of 30% to 60% according to series [<xref ref-type="bibr" rid="scirp.55418-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref15">15</xref>] . It was of 36.75% in our study.</p><p>Cardiac manifestations interest the tree heart tunics with a predilection for pericardia [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] . Pericarditis has been reported on 22.22% of the cases in our study.</p><p>Pleurisy, reported on 11.97% of cases in our series is the most common pulmonary manifestation during SLE [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] . Its frequency varies in literature from 10% up to 52% [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref16">16</xref>] .</p><p>In our countries with high tuberculosis endemicity, it is more often considered like tuberculosis and cured like it. In ours ample, interstitial pneumopathy was the most frequent of pulmonary damages.</p><p>The biological anomalies found in our sample are similar to literature data [<xref ref-type="bibr" rid="scirp.55418-ref5">5</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref7">7</xref>] .</p><p>An anaemia is habitual, and most often inflammatory [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref5">5</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] . It reveals sometimes the SLE. Its frequency varies in literature from 8% up to 67% [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref17">17</xref>] . It was the haematological perturbation most frequently seen in our study (86.32%). This high frequency of anaemia also constitutes one of the black subject particularities [<xref ref-type="bibr" rid="scirp.55418-ref3">3</xref>] . Indeed, during compared studies of SLE realised by Petri [<xref ref-type="bibr" rid="scirp.55418-ref17">17</xref>] between black and white Americans subjects, it has been proved a high anaemia frequency on the black American subject.</p><p>On the other hand, haemolytic anaemia, SLE characteristic is rare [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref16">16</xref>] .</p><p>Leukopenia frequency varies according to series from 18% up to 83% [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref16">16</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref18">18</xref>] . It was slightly elevated (15.38%) in our study. Our frequency was sensibly equal to that of Senegal one [<xref ref-type="bibr" rid="scirp.55418-ref6">6</xref>] , however it was most highest (56%) in Douala’s study in Cameroon [<xref ref-type="bibr" rid="scirp.55418-ref7">7</xref>] . The leukopenia is frequent on the black subject [<xref ref-type="bibr" rid="scirp.55418-ref3">3</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref20">20</xref>] .</p><p>Thrombocytopenia’s frequency varies from 10% up to 26% in the literature [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref20">20</xref>] , it is 13.67% in our sample. Idem for Senegal [<xref ref-type="bibr" rid="scirp.55418-ref6">6</xref>] and Cameroon [<xref ref-type="bibr" rid="scirp.55418-ref7">7</xref>] , it can be associated to haemolytic anaemia (Evans’ syndrome).</p><p>In unanimous way, ANA are quasi-constant in SLE, in fact, antinuclear autoantibodies are positives in most in 90% of the time in African studies: 92% in Tunisia [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] , 95% in Morocco [<xref ref-type="bibr" rid="scirp.55418-ref8">8</xref>] , 100% at Gabon [<xref ref-type="bibr" rid="scirp.55418-ref5">5</xref>] ; 97.8% in Senegal [<xref ref-type="bibr" rid="scirp.55418-ref6">6</xref>] , 94.2% in our study.</p><p>Cameroon alone had a rate below 90% (86.1%). These high rates are the same found in American and European studies (99% on North-American [<xref ref-type="bibr" rid="scirp.55418-ref21">21</xref>] ; 96% in European study [<xref ref-type="bibr" rid="scirp.55418-ref12">12</xref>] and Brazilian [<xref ref-type="bibr" rid="scirp.55418-ref22">22</xref>] .</p><p>Detection of anti DNA native autoantibodies in our study was 73.53%. This frequency was similar to the one observed in Africa (Tunisia [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] , Morocco [<xref ref-type="bibr" rid="scirp.55418-ref8">8</xref>] , Cameroon [<xref ref-type="bibr" rid="scirp.55418-ref7">7</xref>] ) and North America [<xref ref-type="bibr" rid="scirp.55418-ref21">21</xref>] and in Europe [<xref ref-type="bibr" rid="scirp.55418-ref12">12</xref>] but it was clearly far high than Gabonese study [<xref ref-type="bibr" rid="scirp.55418-ref5">5</xref>] or Senegalese [<xref ref-type="bibr" rid="scirp.55418-ref6">6</xref>] where Anti-DNA natives, haven’t been positives on respectively 63.8% and 45.7% of cases. This can be explained by the variable sensitivity of the different research technics indeed the anti-DNA natives frequency vary from 35% up to 98% depending on series and technics used [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref23">23</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref25">25</xref>] .</p><p>Elevated rates of anti-DNA native’s autoantibodies are specific from SLE. The anti-DNA native’s autoantibodies rate is correlated to a serious kidney damage existence, and to the Systemic Lupus Erythematous evolution [<xref ref-type="bibr" rid="scirp.55418-ref26">26</xref>] .</p><p>Extractable nuclear anti-antigens autoantibodies frequency during SLE, also varies depending on the sensibility of the methods used, depending on series and sometimes depending on ethnic origin [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] .</p><p>Anti-Sm autoantibodies are exclusively present on lupic patients.</p><p>Their incidence varies from 12% up to 52% [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref28">28</xref>] . The anti-Sm’s sensibility is particularly elevated on black subjects, in order of 50% [<xref ref-type="bibr" rid="scirp.55418-ref3">3</xref>] - [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref20">20</xref>] , compared to the Caucasian population, where anti-Sm are found on only 10% to 20% of SLE cases [<xref ref-type="bibr" rid="scirp.55418-ref12">12</xref>] . This has been confirmed in the Senegalese series [<xref ref-type="bibr" rid="scirp.55418-ref7">7</xref>] and in ours, where the anti-SM frequency was elevated respectively in 65.2% and 75% of cases respectively. However, it was clearly lower in the Gabonese series (33.33%) [<xref ref-type="bibr" rid="scirp.55418-ref5">5</xref>] . This low frequency could be explained by the realisation technics. ELISA technic is actually the reference method [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] .</p><p>Anti-RNP was present in all our patients (100%) versus 66% in the Tunisian series [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] and 78.3% at Senegal [<xref ref-type="bibr" rid="scirp.55418-ref6">6</xref>] . Anti-ribonucl&#233;oproteins autoantibodies (anti-RNP) can been observed on 20% to 30% of lupus, but are not specific to Systemic lupus erythematous [<xref ref-type="bibr" rid="scirp.55418-ref29">29</xref>] . However, it has been showed a more high frequency of anti- RNP on the black African [<xref ref-type="bibr" rid="scirp.55418-ref3">3</xref>] . Indeed, during compared studies of clinical and biological manifestations between black Africans and Caucasians living in Europe [<xref ref-type="bibr" rid="scirp.55418-ref30">30</xref>] or in South Africa [<xref ref-type="bibr" rid="scirp.55418-ref31">31</xref>] , it has been found on black Africans higher frequency of anti-RNP, in addition to myalgia, seritis and kidney insufficiency.</p><p>Anti-SS-A autoantibodies have a high predictive value for SLE diagnosis among the patients tested positive on AAN, but negatives on anti-DNA native autoantibodies or Anti Sm [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] . Indeed, in Simmons O’Brien et al.’s study [<xref ref-type="bibr" rid="scirp.55418-ref32">32</xref>] , he found that 47% of patients with kidney damage had anti-SS-A autoantibodies but not anti- DNA native autoantibodies. Patients with anti-SS-A autoantibodies have to be regularly followed to detect the onset of systemic manifestations [<xref ref-type="bibr" rid="scirp.55418-ref32">32</xref>] . Anti-SSA frequency varies during SLE from 20% to 60% according to series [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref13">13</xref>] , in our study, the frequency was high (75%).</p><p>Anti-SSB autoantibodies, are particularly frequent in primitive Sjogren’ syndrome (60% to 80%) while their frequency in SLE is variable according to series, to 5% up to 35% [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref33">33</xref>] . Their frequency was slightly higher (56.25%) in our study. The elevated frequency of anti SSA and SSB could also be a SLE particularity in black subjects [<xref ref-type="bibr" rid="scirp.55418-ref3">3</xref>] .</p><p>Antiphospholipids frequencies during SLE varies according to series from 17% up to 87% [<xref ref-type="bibr" rid="scirp.55418-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.55418-ref13">13</xref>] . It was 37.50% in our study. It was higher in Tunisian [<xref ref-type="bibr" rid="scirp.55418-ref9">9</xref>] , Senegalese [<xref ref-type="bibr" rid="scirp.55418-ref6">6</xref>] and Cameroonian [<xref ref-type="bibr" rid="scirp.55418-ref7">7</xref>] studies respectively 45% and 50% of cases.</p><p>This study shows an increase in SLE in Ivory Coast and a better knowledge of the clinical and immunological profile by the amelioration of the technical expertise and the growing augmentation of rheumatologists.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Our study confirms the SLE clinical polymorphism on one hand, and on the other hand reveals that the lupic serology of black subjects is rich with the existence of multiple types of antinuclear autoantibodies simultaneously (Anti-DNA, Anti-Sm, Anti-RNP, Anti-SSA, Anti-SSB).</p></sec><sec id="s6"><title>Conflicts of Interests</title><p>Authors have no conflicts of interest to declare.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.55418-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Haddouk, S., Ben Ayed, M., Baklouti, S., Hachicha, J., Bahloul, Z. and Masmoudi, H. (2005) Autoanticorps dans le lupus érythémateux systémique : Profil et corrélations cliniques . Pathologie Biologie, 53, 311-317.http://dx.doi.org/10.1016/j.patbio.2004.10.004</mixed-citation></ref><ref id="scirp.55418-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ghedira, I., Sakly, W. and Jeddi, M. (2002) Caractéristiques cliniques et sérologiques du lupus érythémateux systémique: A propos de 128 cas. Pathologie Biologie, 50, 18-24. http://dx.doi.org/10.1016/S0369-8114(01)00262-0</mixed-citation></ref><ref id="scirp.55418-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Meyer, O. (2002) Lupus systémique chez les non-Caucasiens. Revue du Rhumatisme, 69, 801-808. http://dx.doi.org/10.1016/S1169-8330(02)00385-X</mixed-citation></ref><ref id="scirp.55418-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Daboiko, J.C., Gueret, M., Eti, E., Ouali, B., Ouattara, B., Gbané, M. and Kouakou, N.M. (2004) Profil clinique et évolutif du lupus érythémateux systémique: A propos de 49 cas colligés au CHU de Cocody. Médecine d’Afrique noire, 51, 143-146.</mixed-citation></ref><ref id="scirp.55418-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Iba Ba, J., Nzenze, J.R., Biteghe, B., Missounga, L., Bignoumba Ibouili, R., Moussavou Kombila, J.B. and Boguikouma, J.B. (2011) Profil clinique, biologique et évolutif du lupus systémique en milieu hospitalier à Libreville. Médecine d’Afrique noire, 58, 551-559.</mixed-citation></ref><ref id="scirp.55418-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Fall, S., Pouye, A., Ndiaye, F.S., Ndongo, S., Leye,Y., Diouma,A., Dieng, M.T., Ka, E.F., Ka, M.M. and Moreira-Diop, T. (2011) Présentation initiale du lupus érythémateux systémique au Sénégal. Médecine d’Afrique noire, 58, 156-160.</mixed-citation></ref><ref id="scirp.55418-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Doualla Bija, M., Luma Namme, H., Ashuntantang, G., Epée, H., Kemta, F., Kwedi, F., Ngatat, C. and Ngandeu Singwe, M. (2014) Clinical Presentation, Treatment and Outcome of Patients with Systemic Lupus Erythematosus Seen at a Rheumatology Clinic in Douala, Cameroon. Health Sciences and Disease, 15, 1-5.</mixed-citation></ref><ref id="scirp.55418-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Bouatba, L., Bachir, H., Ammouri, W., Maamar, M., Harmouche, H., Adnaoui, M. and Tazi Mezalek, Z. (2014) Lupus érythémateux systémique au Maroc: Etude analytique monocentrique de 440 patients. Revue de médecine interne, 35, A96-A200.http://dx.doi.org/10.1016/j.revmed.2014.10.243</mixed-citation></ref><ref id="scirp.55418-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Louzir, B., Othmani, S. and Ben Abdelhafidh, N. (2003) Le lupus érythémateux systémique en Tunisie. étude multi- centrique nationale. à propos de 295 observations. La revue de médecine interne, 24, 768-774.http://dx.doi.org/10.1016/S0248-8663(03)00250-9</mixed-citation></ref><ref id="scirp.55418-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Vilá, L.M., Mayor, A.M., Valentín, A.H., Garcia-Soberal, M. and Vilá, S. (1999) Clinical and Immunological Manifestations in 134 Puerto Rican Patients with Systemic Lupus Erythematosus. Lupus, 8, 279-286.http://dx.doi.org/10.1191/096120399678847803</mixed-citation></ref><ref id="scirp.55418-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Al-Attia, H.M. and Al-Ahmed, Y.H. (1998) Mucocutaneous Disease in Arabs with SLE: Clinical Expression and Relevance to Autoantibodies. Lupus, 7, 535-539.http://dx.doi.org/10.1191/096120398678920569</mixed-citation></ref><ref id="scirp.55418-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cervera, R., Khamashta, M.A., Font, J., Sebastiani, G.D., Gil, A., Lavilla, P., et al. (1993) Systemic Lupus Erythematosus: Clinical and Immunological Patterns of Disease Expression in a Cohort of 1000 Patients. The European Working Party on Systemic Lupus Erythematosus. Medicine, 72, 113-124.http://dx.doi.org/10.1097/00005792-199303000-00005</mixed-citation></ref><ref id="scirp.55418-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Al Mekaimi, A., Malaviya, A.N., Serebour, F., Umamaheswaran, I., Kumar, R., Al-Saeid, K. and Sharma, P. (1997) Serological Characteristics of Systemic Lupus Erythematosus from a Hospital-Based Rheumatology Clinic in Kuwait. Lupus, 6, 668-674.http://dx.doi.org/10.1177/096120339700600808</mixed-citation></ref><ref id="scirp.55418-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">West, S.G. (1996) Lupus and the Central Nervous System. Current Opinion in Rheumatology, 8, 408-414.http://dx.doi.org/10.1097/00002281-199609000-00004</mixed-citation></ref><ref id="scirp.55418-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology Nomenclature and Case Definitions for Neuropsychiatric Lupus Syndromes. Arthritis &amp; Rheumatology, 42, 599-608.</mixed-citation></ref><ref id="scirp.55418-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Uthman, I., Nasr, F., Kassak, K. and Masri, A.B. (1999) Systemic Lupus Erythematosus in Lebanon. Lupus, 8, 713-715.http://dx.doi.org/10.1191/096120399678841016</mixed-citation></ref><ref id="scirp.55418-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Petri, M. (1997) The Effect of Race on the Presentation and Course of SLE in the United States. Arthritis &amp; Rheumatology, 40, S162.</mixed-citation></ref><ref id="scirp.55418-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Al-Jarallah, K., Al-Awadi, A., Siddiqui, H., Al-Salim, I., Shehab, D., Umamaheswaran, I., et al. (1998) Systemic Lupus Erythematosus in Kuwait Hospital Based Study. Lupus, 7, 434-438.http://dx.doi.org/10.1191/096120398678920389</mixed-citation></ref><ref id="scirp.55418-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Vilarinho, S.T. and Lavras-Costallat, L.T. (1998) Evaluation of the Hypothalamic-Pituitary-Gonadal Axis in Males with Systemic Lupus Erythematosus. Journal of Rheumatology, 25, 1097-103.</mixed-citation></ref><ref id="scirp.55418-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Meyer, O., Lupus érythémateux aigu disséminé (1997) Diagnostic, évolution, principes du traitement. Revue du Praticien, 47, 821-831.</mixed-citation></ref><ref id="scirp.55418-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., Mc Shane, D.J., Rothfield, N.F., et al. (1982) The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis &amp; Rheumatology, 25, 1271-1277.http://dx.doi.org/10.1002/art.1780251101</mixed-citation></ref><ref id="scirp.55418-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Chahade, W.H., Sato, E.L., Moura, J.E., Costallat, L.T.L. and Andrate, L.E.C. (1995) Systemic Lupus Erythematosus in Sao Paulo/Brazil: A Clinical and Laboratory Overview. Lupus, 4, 100-103.http://dx.doi.org/10.1177/096120339500400204</mixed-citation></ref><ref id="scirp.55418-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Molina, J.F., Molina, J., Garcia, C., Gharavi, A.E., Wilson, W.A. and Espinoza, L.R. (1997) Ethnic Differences in the Clinical Expression of Systemic Lupus Erythematosus: A Comparative Study between African-American and Latin American. Lupus, 6, 63-67.http://dx.doi.org/10.1177/096120339700600109</mixed-citation></ref><ref id="scirp.55418-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Lopez-Longo, F.J., Monteagudo, I., Gonzalez, C.M., Grau, R. and Carreno, L. (1998) Anti-BB’-Sm Antibodies, Anticardiolipin Antibodies and Thrombosis in Systemic Lupus Erythematosus. The Journal of Rheumatology, 25, 1743- 1749.</mixed-citation></ref><ref id="scirp.55418-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Lenert, P., Felle, D., Lenert, G., Mitic, I., Curic, S. and Vodopivec, S. (1993) Immunologic Characterization of Autoreactivity to Nuclear Antigens in Patients with Systemic Lupus Erythematosus. Medicinski Pregled, 46, 167-172.</mixed-citation></ref><ref id="scirp.55418-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Fournel, S. and Levastre, P. (2000) Les autoanticorps dans le lupus. Médecine Thérapeutique, 6, 537-546.</mixed-citation></ref><ref id="scirp.55418-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Pan, L.T., Tin, S.K., Boey, M.L. and Fong, K.Y. (1998) The Sensitivity and Specificity of Auto-Antibodies to the Sm Antigen in the Diagnosis of Systemic Lupus Erythematosus. Annals Academy of Medicine Singapore, 27, 21-23.</mixed-citation></ref><ref id="scirp.55418-ref28"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meyer</surname><given-names> O. </given-names></name>,<etal>et al</etal>. (<year>1999</year>)<article-title>Biologie du lupus érythémateux systémique</article-title><source> Revue du Rhumatisme</source><volume> 66</volume>,<fpage> 75s</fpage>-<lpage>80s</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.55418-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Goetz, M. (2005) Marqueurs biologiques anciens et modernes du lupus erythémateux systémique. Revue du Rhumatisme, 72, 134-141.http://dx.doi.org/10.1016/j.rhum.2004.12.007</mixed-citation></ref><ref id="scirp.55418-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Amoura, Z., Du, L.T.H., Cacoub, P., Frances, C. and Piette, J.C. (1999) Systemic Lupus Erythematosus in Patients Native to West and Central Africa: Comment on the Article by Bae et al. Arthritis &amp; Rheumatism, 42, 1560-1561.http://dx.doi.org/10.1002/1529-0131(199907)42:7&lt;1560::AID-ANR42&gt;3.0.CO;2-L</mixed-citation></ref><ref id="scirp.55418-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Morrisson, R.C.A., Gear, A.J., Kark, A., Meyers, A. and Goldberg, B. (1990) Differences in Systemic Lupus Erythematosus among 4 Racial Groups in South Africa. Arthritis &amp; Rheumatism, 33, S104.</mixed-citation></ref><ref id="scirp.55418-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Simmons-O’Brien, E., Chen, S., Watson, R., Antoni, C., Petri, M., Hochberg, M., et al. (1995) One Hundred Anti-Ro (SS-A) Antibody Positive Patients: A 10 Year Follow-Up. Medicine, 74, 109-130.http://dx.doi.org/10.1097/00005792-199505000-00001</mixed-citation></ref><ref id="scirp.55418-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Buján, S., Ordi-Ros, J., Paredes, J., Mauri, M., Matas, L., Cortés, J. and Vilardell, M. (2003) Contribution of the Initial Features of Systemic Lupus Erythematosus to the Clinical Evolution and Survival of a Cohort of Mediterranean Patients. Annals of the Rheumatic Diseases, 62, 859-865.</mixed-citation></ref></ref-list></back></article>